NESS ZIONA, Israel and NEW YORK–(BUSINESS WIRE)–SmartZyme, a biopharmaceutical company utilizing the proprietary Provolution™ platform for protein design and engineering of both new and better therapeutics, announces the closing of a $4 million investment by OrbiMed, a leading healthcare investment firm. SmartZyme also named Nissim Darvish, M.D., Ph.D., senior managing director at OrbiMed Israel, and Stephen Squinto, Ph.D., venture partner at OrbiMed, to its board of directors. “OrbiMed is among the world’s most highly regarded healthcare investors and we are proud to have their backing and vote of confidence in our business,” said Shilo Ben-Zeev, co-founder and chief executive officer...